WO2026119209 - METHOD FOR TREATING OR PREVENTING EYE DISEASE
National phase entry is expected:
Publication Number
WO/2026/119209
Publication Date
11.06.2026
International Application No.
PCT/CN2025/139852
International Filing Date
03.12.2025
Title **
[English]
METHOD FOR TREATING OR PREVENTING EYE DISEASE
[French]
MÉTHODE DE TRAITEMENT OU DE PRÉVENTION D'UNE MALADIE OCULAIRE
[Chinese]
用于治疗或预防眼部疾病的方法
Applicants **
GAN & LEE PHARM CO LTD
Inventors
JIAO, Jiao
CUI, Zhengzhi
YE, Rongcai
Priority Data
202411764007.0
03.12.2024
CN
202511147796.8
15.08.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1933 | |
| EPO | Filing, Examination, Granting | 13123 | |
| Japan | Filing, Examination, Granting | 2234 | |
| South Korea | Filing, Examination, Granting | 2264 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,294
Contact Us
Abstract[English]
The present invention relates to the technical field of gene therapy, and in particular to a method for treating or preventing an eye disease. The method comprises: administering to the eye of a subject in need thereof a recombinant adeno-associated virus (rAAV) comprising a nucleotide sequence encoding a therapeutic product. The rAAV comprises a nucleic acid, the nucleic acid comprises a coding sequence, and the coding sequence is a nucleotide sequence encoding an anti-vascular endothelial growth factor (VEGF) fusion protein or an anti-VEGF antibody. Delivery of the therapeutic product is achieved by means of gene therapy to continuously supply the therapeutic product in the eye.[French]
La présente invention relève du domaine technique de la thérapie génique, et concerne en particulier une méthode de traitement ou de prévention d'une maladie oculaire. La méthode comprend : l'administration dans l’œil d'un sujet qui en a besoin d'un virus adéno-associé recombinant (rVAA) comprenant une séquence nucléotidique codant pour un produit thérapeutique. Le rVAA comprend un acide nucléique, l'acide nucléique comprend une séquence codante, et la séquence codante est une séquence nucléotidique codant pour une protéine de fusion du facteur de croissance endothéliale vasculaire (VEGF) ou un anticorps anti-VEGF. L'administration du produit thérapeutique est obtenue au moyen d'une thérapie génique pour administrer en continu le produit thérapeutique dans l’œil.[Chinese]
属于基因治疗技术领域，具体涉及一种用于治疗或预防眼部疾病的方法，所述方法包括向有需要的受试者的眼部施用包含编码治疗性产物的核苷酸序列的重组腺相关病毒。rAAV包含核酸，核酸包含编码序列，编码序列是编码抗血管内皮生长因子(VEGF)融合蛋白或抗VEGF抗体的核苷酸序列。所述治疗性产物的递送经由基因疗法完成，以在眼睛中连续供应治疗性产物。